Finding 1166791 (2024-009)

Material Weakness Repeat Finding
Requirement
B
Questioned Costs
-
Year
2024
Accepted
2025-12-29

AI Summary

  • Core Issue: Unallowable administrative costs, specifically marketing and financing expenses, were incorrectly charged as direct expenses to UC grants.
  • Impacted Requirements: Costs must adhere to federal regulations, which state that certain marketing and interest costs are unallowable unless approved.
  • Recommended Follow-Up: Re-establish internal controls to monitor allowable expenses and ensure proper reconciliation of costs with cash draws.

Finding Text

Finding: Unallowable administrative costs charged as direct expenses. Criteria: Allowable Costs/ Cost Principles (Non-profit Organization) Per the Code of Federal Regulations § 75.467 Selling and marketing costs., costs of selling and marketing any products or services of the non-Federal entity (unless allowed under § 75.421) are unallowable, except as direct costs, with prior approval by the HHS awarding agency when necessary for the performance of the Federal award. Per the Code of Federal Regulations § 200.449 Interest, costs incurred for interest on borrowed capital, temporary use of endowment funds, or the use of the recipient's or subrecipient's own funds are unallowable. Condition and Context, and Cause: During our audit, we identified unallowable marketing and financing expenditures allocated to the UC grants. See discussion above at 2024-006 for background on failure to track allowable costs. Result: Amounts identified as unallowable costs per the compliance guidance have been included in the contract liability as disclosed in Note 12. See the Summary of Unallowable Costs and Questioned Costs tables for detail on page 56. Recommendation: The auditors recommend the Organization re-implement internal controls to track allowable expenditures and reconcile qualifying costs with cash draws.

Corrective Action Plan

Cayuga Centers does not fully understand the scope of this asserted finding. It will, however, work with its auditors to fully assess this finding. As discussed above, Cayuga Centers has engaged grants management advisors who will assist in evaluating the scope of this asserted findings. To the extent that the costs referenced in this finding are unallowable, Cayuga Centers will address the matter with its primary funding agency as part of broader resolution of any unallowable costs. To the extent this finding asserts control failures, please see Cayuga Centers’ response to Findings 2024-005 and 006 above.

Categories

Allowable Costs / Cost Principles

Other Findings in this Audit

  • 1166741 2024-003
    Material Weakness Repeat
  • 1166742 2024-004
    Material Weakness Repeat
  • 1166743 2024-005
    Material Weakness Repeat
  • 1166744 2024-006
    Material Weakness Repeat
  • 1166745 2024-007
    Material Weakness Repeat
  • 1166746 2024-008
    Material Weakness Repeat
  • 1166747 2024-009
    Material Weakness Repeat
  • 1166748 2024-010
    Material Weakness Repeat
  • 1166749 2024-011
    Material Weakness Repeat
  • 1166750 2024-012
    Material Weakness Repeat
  • 1166751 2024-013
    Material Weakness Repeat
  • 1166752 2024-003
    Material Weakness Repeat
  • 1166753 2024-004
    Material Weakness Repeat
  • 1166754 2024-005
    Material Weakness Repeat
  • 1166755 2024-006
    Material Weakness Repeat
  • 1166756 2024-007
    Material Weakness Repeat
  • 1166757 2024-008
    Material Weakness Repeat
  • 1166758 2024-009
    Material Weakness Repeat
  • 1166759 2024-010
    Material Weakness Repeat
  • 1166760 2024-011
    Material Weakness Repeat
  • 1166761 2024-012
    Material Weakness Repeat
  • 1166762 2024-013
    Material Weakness Repeat
  • 1166763 2024-003
    Material Weakness Repeat
  • 1166764 2024-004
    Material Weakness Repeat
  • 1166765 2024-005
    Material Weakness Repeat
  • 1166766 2024-006
    Material Weakness Repeat
  • 1166767 2024-007
    Material Weakness Repeat
  • 1166768 2024-008
    Material Weakness Repeat
  • 1166769 2024-009
    Material Weakness Repeat
  • 1166770 2024-010
    Material Weakness Repeat
  • 1166771 2024-011
    Material Weakness Repeat
  • 1166772 2024-012
    Material Weakness Repeat
  • 1166773 2024-013
    Material Weakness Repeat
  • 1166774 2024-003
    Material Weakness Repeat
  • 1166775 2024-004
    Material Weakness Repeat
  • 1166776 2024-005
    Material Weakness Repeat
  • 1166777 2024-006
    Material Weakness Repeat
  • 1166778 2024-007
    Material Weakness Repeat
  • 1166779 2024-008
    Material Weakness Repeat
  • 1166780 2024-009
    Material Weakness Repeat
  • 1166781 2024-010
    Material Weakness Repeat
  • 1166782 2024-011
    Material Weakness Repeat
  • 1166783 2024-012
    Material Weakness Repeat
  • 1166784 2024-013
    Material Weakness Repeat
  • 1166785 2024-003
    Material Weakness Repeat
  • 1166786 2024-004
    Material Weakness Repeat
  • 1166787 2024-005
    Material Weakness Repeat
  • 1166788 2024-006
    Material Weakness Repeat
  • 1166789 2024-007
    Material Weakness Repeat
  • 1166790 2024-008
    Material Weakness Repeat
  • 1166792 2024-010
    Material Weakness Repeat
  • 1166793 2024-011
    Material Weakness Repeat
  • 1166794 2024-012
    Material Weakness Repeat
  • 1166795 2024-013
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.676 UNACCOMPANIED CHILDREN PROGRAM $5.28M
93.959 BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE $260,463